Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SP-3164 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

NCT05979857 is registered in ClinicalTrials.gov with Salarius Pharmaceuticals, LLC as lead sponsor.

NCT NCT05979857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05979857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SP-3164 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma
Lead sponsor
Salarius Pharmaceuticals, LLC
Phase
Phase 1
Overall status
Not yet recruiting
Start date
March 15, 2024
Completion date
August 15, 2027
Enrollment
72 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin's, adult